US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Insight Molecular Diagnostics Inc.

3.56

-0.5500-13.38%

Post-market: 3.800.2403+6.75%18:10 EDT

Volume:341.80K

Turnover:1.26M

Market Cap:114.44M

PE:-1.26

High:4.37

Open:4.17

Low:3.29

Close:4.11

52wk High:8.51

52wk Low:2.33

Shares:32.15M

Float Shares:11.26M

Volume Ratio:1.59

T/O Rate:3.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8272

EPS(LYR):-4.6612

ROE:-23603.11%

ROA:-28.44%

PB:-12.44

PE(LYR):-0.76

Loading ...

Overview Company News Filings

Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)

Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet

Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year

Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million

Insight Molecular Diagnostics Inc - Reports Q4 2025 Net Loss of $23.0 Mln or $0.72 per Share

THOMSON REUTERS

Insight Molecular Diagnostics Inc - Expect U.k. Ce Marking via Self-Certification in Q2 2026

THOMSON REUTERS

Imdx Submits Graftassuredx for FDA Review and Reports Q4 2025 Results

THOMSON REUTERS

Press Release: IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience

Calendar of U.S. Earnings Expected in the Week Ahead

Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview

Calendar of U.S. Earnings Expected in the Week Ahead

Insight Molecular Diagnostics publishes financial calendar update

Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview

Insight Molecular Diagnostics reports 249-patient study showing GraftAssure CM-score outperforms dd-cfDNA percentage measures

Second Study Affirms Superiority of Imdx Graftassure Assay’s Proprietary Dd-Cfdna Combination Model Score

THOMSON REUTERS

BRIEF-Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission

Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)

BRIEF-Insight Molecular Diagnostics Enters Agreement With Quest Diagnostics - SEC Filing

Insight Molecular Diagnostics Inc - Quest Diagnostics to Provide Specimen Collection Services - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMDX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","market":"US","secType":"STK","nameCN":"Insight Molecular Diagnostics Inc.","latestPrice":3.56,"timestamp":1774641600000,"preClose":4.11,"halted":0,"volume":341804,"hourTrading":{"tag":"盘后","latestPrice":3.8003,"preClose":3.56,"latestTime":"18:10 EDT","volume":1347,"amount":5075.8459,"timestamp":1774649431875,"change":0.2403,"changeRate":0.0675,"amplitude":0.11236},"delay":0,"changeRate":-0.13381995133819957,"floatShares":11264900,"shares":32146900,"eps":-2.8272,"marketStatus":"Market Closed","change":-0.55,"latestTime":"03-27 16:00:00 EDT","open":4.17,"high":4.37,"low":3.291,"amount":1256332.2872308001,"amplitude":0.26253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.8272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":4.11,"preHourTrading":{"tag":"盘前","latestPrice":3.85,"preClose":4.11,"latestTime":"09:29 EDT","volume":2515,"amount":10049.693027,"timestamp":1774618164746,"change":-0.26,"changeRate":-0.06326,"amplitude":0.13382},"postHourTrading":{"tag":"盘后","latestPrice":3.8003,"preClose":3.56,"latestTime":"18:10 EDT","volume":1347,"amount":5075.8459,"timestamp":1774649431875,"change":0.2403,"changeRate":0.0675,"amplitude":0.11236},"volumeRatio":1.58505,"impliedVol":8.6435,"impliedVolPercentile":0.9247},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMDX\",,,,,undefined,":{"symbol":"IMDX","floatShares":11264900,"roa":"-28.44%","roe":"-23603.11%","lyrEps":-4.661158,"volumeRatio":1.58505,"shares":32146900,"dividePrice":0,"high":4.37,"amplitude":0.26253,"preClose":4.11,"low":3.291,"week52Low":2.33,"pbRate":"-12.44","psRate":"26.00","week52High":8.51,"institutionHeld":0,"latestPrice":3.56,"eps":-2.8272,"divideRate":0,"volume":341804,"delay":0,"ttmEps":-2.8272,"open":4.17,"prevYearClose":7.5,"prevWeekClose":4.26,"prevMonthClose":6.01,"prevQuarterClose":7.5,"fiveDayClose":4.26,"twentyDayClose":6.01,"sixtyDayClose":7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMDX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-26","symbol":"IMDX","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-11-10","symbol":"IMDX","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2025-08-11","symbol":"IMDX","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-0.3},{"market":"US","date":"2025-05-12","symbol":"IMDX","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"post","actualEps":-0.26},{"market":"US","date":"2025-03-24","symbol":"IMDX","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":0.48}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMDX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IMDX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1743220800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IMDX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IMDX","date":"2026-03-27","current":-1.259196,"percent":0.549223,"low":-3.993147,"twenty":-3.007939,"median":-2.401676,"eighty":-1.395447,"high":-1.083107,"avg":-2.254698,"sd":0.804726,"marketCap":132204561},"quantilePoints":[{"date":"2025-06-20","current":-1.55268,"twenty":-1.55268,"median":-1.55268,"eighty":-1.55268,"marketCap":90373740},{"date":"2025-06-27","current":-1.655864,"twenty":-1.798357,"median":-1.675518,"eighty":-1.638667,"marketCap":96379590},{"date":"2025-07-03","current":-1.40036,"twenty":-1.71581,"median":-1.6055,"eighty":-1.491752,"marketCap":81507962},{"date":"2025-07-11","current":-1.420014,"twenty":-1.663726,"median":-1.493717,"eighty":-1.427876,"marketCap":82651933},{"date":"2025-07-18","current":-1.390533,"twenty":-1.642106,"median":-1.471607,"eighty":-1.399377,"marketCap":80935976},{"date":"2025-07-25","current":-1.454409,"twenty":-1.585601,"median":-1.459323,"eighty":-1.399377,"marketCap":84653883},{"date":"2025-08-01","current":-1.238213,"twenty":-1.556611,"median":-1.424927,"eighty":-1.390533,"marketCap":72070198},{"date":"2025-08-08","current":-1.289805,"twenty":-1.50551,"median":-1.405274,"eighty":-1.357121,"marketCap":75073123},{"date":"2025-08-15","current":-1.083107,"twenty":-1.489787,"median":-1.40036,"eighty":-1.288331,"marketCap":68687397},{"date":"2025-08-22","current":-1.119211,"twenty":-1.488804,"median":-1.395447,"eighty":-1.253936,"marketCap":70976977},{"date":"2025-08-29","current":-1.132749,"twenty":-1.484873,"median":-1.380706,"eighty":-1.161632,"marketCap":71835569},{"date":"2025-09-05","current":-1.114698,"twenty":-1.480942,"median":-1.363484,"eighty":-1.138165,"marketCap":70690780},{"date":"2025-09-12","current":-1.435117,"twenty":-1.467185,"median":-1.353884,"eighty":-1.132749,"marketCap":91010801},{"date":"2025-09-19","current":-1.520863,"twenty":-1.485856,"median":-1.368397,"eighty":-1.138165,"marketCap":96448554},{"date":"2025-09-26","current":-1.47122,"twenty":-1.485856,"median":-1.389987,"eighty":-1.149898,"marketCap":93300381},{"date":"2025-10-03","current":-1.507324,"twenty":-1.490769,"median":-1.392517,"eighty":-1.163437,"marketCap":95589961},{"date":"2025-10-10","current":-1.714919,"twenty":-1.500103,"median":-1.395447,"eighty":-1.171561,"marketCap":108755046},{"date":"2025-10-17","current":-2.087237,"twenty":-1.528084,"median":-1.402817,"eighty":-1.173366,"marketCap":132366339},{"date":"2025-10-24","current":-2.897311,"twenty":-1.598867,"median":-1.417558,"eighty":-1.192321,"marketCap":183738788},{"date":"2025-10-31","current":-2.67392,"twenty":-1.674528,"median":-1.432479,"eighty":-1.204957,"marketCap":169572012},{"date":"2025-11-07","current":-2.933415,"twenty":-1.775372,"median":-1.457682,"eighty":-1.224911,"marketCap":186028368},{"date":"2025-11-14","current":-3.696486,"twenty":-2.084901,"median":-1.473476,"eighty":-1.250005,"marketCap":224665029},{"date":"2025-11-21","current":-2.862765,"twenty":-2.669859,"median":-1.478977,"eighty":-1.260815,"marketCap":173993132},{"date":"2025-11-28","current":-2.895779,"twenty":-2.764631,"median":-1.48389,"eighty":-1.270643,"marketCap":175999643},{"date":"2025-12-05","current":-2.631669,"twenty":-2.764631,"median":-1.488804,"eighty":-1.282435,"marketCap":159947558},{"date":"2025-12-12","current":-2.452451,"twenty":-2.743778,"median":-1.493785,"eighty":-1.285383,"marketCap":149055072},{"date":"2025-12-19","current":-2.447735,"twenty":-2.714849,"median":-1.505068,"eighty":-1.294719,"marketCap":148768428},{"date":"2025-12-26","current":-2.744859,"twenty":-2.739199,"median":-1.51635,"eighty":-1.307003,"marketCap":166827023},{"date":"2026-01-02","current":-3.537189,"twenty":-2.766436,"median":-1.545684,"eighty":-1.326657,"marketCap":214983277},{"date":"2026-01-09","current":-3.537189,"twenty":-2.848616,"median":-1.572334,"eighty":-1.341398,"marketCap":214983277},{"date":"2026-01-16","current":-3.122159,"twenty":-2.895779,"median":-1.658314,"eighty":-1.353884,"marketCap":189758572},{"date":"2026-01-23","current":-3.150456,"twenty":-2.900495,"median":-1.677968,"eighty":-1.357494,"marketCap":191478439},{"date":"2026-01-30","current":-3.122159,"twenty":-2.986727,"median":-1.755536,"eighty":-1.360521,"marketCap":189758572},{"date":"2026-02-06","current":-3.155173,"twenty":-3.018554,"median":-1.819819,"eighty":-1.364943,"marketCap":191765083},{"date":"2026-02-13","current":-2.951395,"twenty":-3.074996,"median":-2.083343,"eighty":-1.369886,"marketCap":179379897},{"date":"2026-02-20","current":-2.87381,"twenty":-3.072166,"median":-2.244936,"eighty":-1.382344,"marketCap":174664420},{"date":"2026-02-27","current":-3.000829,"twenty":-3.054013,"median":-2.378582,"eighty":-1.390315,"marketCap":182384395},{"date":"2026-03-06","current":-2.900272,"twenty":-3.054013,"median":-2.405289,"eighty":-1.390533,"marketCap":176272748},{"date":"2026-03-13","current":-2.588017,"twenty":-3.035708,"median":-2.450093,"eighty":-1.392913,"marketCap":157294478},{"date":"2026-03-20","current":-2.074647,"twenty":-3.019142,"median":-2.42887,"eighty":-1.395068,"marketCap":126092915},{"date":"2026-03-27","current":-2.175204,"twenty":-3.007939,"median":-2.401676,"eighty":-1.395447,"marketCap":132204561}],"updateTime":1774700211650},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMDX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622582450","title":"Analysts Are Bullish on Top Healthcare Stocks: Insight Molecular Diagnostics (IMDX), Tango Therapeutics (TNGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622582450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622582450?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:50","pubTimestamp":1774615848,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insight Molecular Diagnostics (IMDX), Tango Therapeu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insight-molecular-diagnostics-imdx-tango-therapeutics-tngx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-insight-molecular-diagnostics-imdx-tango-therapeutics-tngx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","TNGX","BK4588","BK4581","IMDX","BLSG","LU0128526141.USD","BK4139","BK4137","BK4585","LU0029874061.USD","BK4112","BLSX"],"gpt_icon":0},{"id":"2622847173","title":"Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847173?lang=en_us&edition=fundamental","pubTime":"2026-03-27 17:55","pubTimestamp":1774605320,"startTime":"0","endTime":"0","summary":"Analyst Michael Matson of Needham maintained a Buy rating on Insight Molecular Diagnostics, retaining the price target of $9.00. Michael Matson has...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-imdx-driven-by-strong-graftassure-traction-upcoming-fda-catalyst-and-solid-balance-sheet-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-imdx-driven-by-strong-graftassure-traction-upcoming-fda-catalyst-and-solid-balance-sheet-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","IMDX"],"gpt_icon":0},{"id":"2622989625","title":"Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989625","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989625?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:10","pubTimestamp":1774555805,"startTime":"0","endTime":"0","summary":"Insight Molecular (NASDAQ:IMDX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 13.92 percent. This is a 3.57 percent increase over losses of $(0.28) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51495180/insight-molecular-q4-adj-eps-0-27-misses-0-24-estimate-sales-1-139m-down-from-1-486m-last-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Insight Molecular Q4 Adj. EPS $(0.27) Misses $(0.24) Estimate, Sales $1.139M Down From $1.486M Last Year","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2622466896","title":"Insight Molecular Diagnostics FY2025 revenue rises 115.79% to $4.1 million; operating expenses climb 37% to $53.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622466896","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622466896?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555787,"startTime":"0","endTime":"0","summary":"iMDx published a shareholder letter alongside its fourth-quarter and full-year 2025 financial results, reporting full-year revenue of USD 4.1 million, up 115.8% year over year.Fourth-quarter revenue was USD 1.1 million, with gross profit of USD 496,000 and gross margin of 43.5%.Operating expenses in the quarter were USD 23.9 million, including USD 14.6 million of non-cash intangible asset impairment losses.Net loss for the quarter was USD 23.0 million, or USD 0.72 per share, while adjusted net loss was USD 8.7 million, or USD 0.27 per share.Management said it submitted the GraftAssureDx kidney transplant rejection test for FDA review and is planning for an FDA-authorized product this year, while guiding to average cash burn of about USD 7.5 million per quarter in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL7Y4TcY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IMDX","BK4139","MDIT"],"gpt_icon":0},{"id":"2622899372","title":"Insight Molecular Diagnostics Inc - Reports Q4 2025 Net Loss of $23.0 Mln or $0.72 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899372?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUASJM1F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2622899309","title":"Insight Molecular Diagnostics Inc - Expect U.k. Ce Marking via Self-Certification in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899309?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUASJM1F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2622689694","title":"Imdx Submits Graftassuredx for FDA Review and Reports Q4 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689694?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUASJM1F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2622896149","title":"Press Release: IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896149?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"-- Welcomed second favorable head-to-head data set from an independent study. at large hospital comparing GraftAssure to a leading centralized. -- Expect U.K. CE marking via self-certification in Q2 2026. -- Completed $26 million financing in February; funds intended to support. expansion into heart transplantation market while also commercializing. We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review. Our FDA submission this week represents the culmination of 12 years of clinical development and three years of highly focused technical product development.In the past three months, we have doubled the number of transplant centers interested in what we are building. We are now engaged with 37 centers in the U.S. and 11 internationally, through our research-use-only assay as well as through our registry study. The 37 centers that we are engaged with in the U.S. include 28 transplant c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","IMDX","BK4139","BK4099","BK4555","BK4585","BK4588","LABU","TM","03160"],"gpt_icon":0},{"id":"2622854237","title":"Plus Therapeutics appoints Ron Andrews to board of directors; Andrews brings 35 years of diagnostics experience","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854237","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854237?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:32","pubTimestamp":1774524738,"startTime":"0","endTime":"0","summary":"He previously served as CEO at Clarient and Oncocyte, and has held interim CEO and Executive Chairman roles supporting venture capital portfolio companies.Andrews has been involved in more than USD 600.0 million of capitalization and more than USD 15.0 billion in exits during his career.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLb3Nfbx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1280957306.USD","LU0266013472.USD","LU2357305700.SGD","LU2764263203.CNY","ABT","BK4504","LU0557290698.USD","LU2210150020.SGD","LU1721429402.USD","LU1623119135.USD","LU0011850046.USD","LU0234572021.USD","LU1691799644.USD","LU2125909916.SGD","LU2324357040.USD","BK4121","IMDX","BK4112","LU0316494557.USD","LU1153585028.USD","LU2133065610.SGD","LU1720051108.HKD","TMO","LU2543165471.USD","LU1791710582.SGD","SG9999014013.SGD","IE00BQXX3F31.USD","NEO","LU0208291251.USD","IE00BN0W2W23.USD","LU2264538146.SGD","LU0058720904.USD","LU1712237335.SGD","NDAQ","LU1988902786.USD","PSTV","LU2095319765.USD","LU2433249047.HKD","LU0170899867.USD","IE00B2B36J28.USD","IE0002141913.USD","LU0882574055.USD","BK4535","LU0868494617.USD","IE00B19Z8X17.USD","SG9999014039.USD","LU2089984988.USD","LU0106261612.USD","BK4139","LU0070302665.USD"],"gpt_icon":0},{"id":"2622024521","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622024521","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622024521?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:00","pubTimestamp":1774432800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DERM","AURA","BHST","BNZI","GOVX","CNTB","JILL","MKC","IMDX","JBS","EQ","JEF","AIRO","CGNT","CHWY","BTGO","CDLR","FEMY","IKT","AUTL","CCL","HUMA","CMC","AIRJ","CTAS","DMAC","NKE","HYPD","KOD","BYND","DOO","BITF","CNTA","RNXT","FUL","FDS","KALV","BIRD","BCAX","CGTX","BAK","AGX","ABOS","CNTX","DEFT","EPAC","EDAP","IMNN","CELC"],"gpt_icon":1},{"id":"2622013663","title":"Insight Molecular Diagnostics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013663","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013663?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:24","pubTimestamp":1774383849,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc  expected to post a loss of24cents a share - Earnings Preview Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a fall in quarterly revenue when i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C2P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IMDX","BK4139","MDIT"],"gpt_icon":0},{"id":"2621583774","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2621583774","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621583774?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:00","pubTimestamp":1774260000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FUL","KBH","BAK","FEMY","ABSI","BTGO","CTAS","CNTB","DOO","DERM","IKT","KALV","EVTL","AIR","CCL","BYND","IMDX","EQ","BZAI","GOVX","MXCT","BCAX","CNM","HSAI","GUTS","DPRO","DEFT","HUMA","HYPD","CNTX","ABVX","JEF","AVTX","CELC","CGNT","CNTA","FENC","AGX","EDAP","ABOS","IMNN","CMC","EPAC","AUTL","ACHV","FBRX","JBS","CHWY","BRZE","CNXC"],"gpt_icon":0},{"id":"2620331787","title":"Insight Molecular Diagnostics publishes financial calendar update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620331787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620331787?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:01","pubTimestamp":1774008095,"startTime":"0","endTime":"0","summary":"iMDx will report fourth-quarter financial results after the market closes on March 26, 2026.A live Zoom webinar to discuss the results is scheduled for March 26, 2026 at 2:00 pm PT / 5:00 pm ET, with registration at iMDx Q4 2025 Earnings Webinar.CEO Josh Riggs and CFO Andrea James are scheduled for a virtual fireside chat on April 15, 2026 at the Needham Virtual Healthcare Conference, with a webcast link at Click here.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL1fJ70J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IMDX","BK4112","BK4585","SG9999014013.SGD","MDIT","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2W23.USD","BK4588","NDAQ","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4082","IE00B64PRP62.GBP","BK4139"],"gpt_icon":0},{"id":"2620738395","title":"Insight Molecular Diagnostics Inc  expected to post a loss of 24 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738395","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738395?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:22","pubTimestamp":1774005724,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics Inc  expected to post a loss of24cents a share - Earnings Preview Insight Molecular Diagnostics Inc IMDX.OQ IMDX.O is expected to  show a fall in quarterly revenue when i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4080WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","MDIT","BK4139","BK4082"],"gpt_icon":0},{"id":"2619402194","title":"Insight Molecular Diagnostics reports 249-patient study showing GraftAssure CM-score outperforms dd-cfDNA percentage measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2619402194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619402194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:05","pubTimestamp":1773403515,"startTime":"0","endTime":"0","summary":"Insight Molecular Diagnostics reports 249-patient study showing GraftAssure CM-score outperforms dd-cfDNA percentage measures. iMDx reported a peer-reviewed study in Transplant International titled “Donor-Derived Cell-Free DNA as a Non-Invasive Readout of Activity Across the Rejection Continuum,” conducted by investigators at Heidelberg University Hospital and Charité – Universittsmedizin Berlin. The multi-center analysis included 249 biopsy-matched kidney transplant patients from two cohorts and compared blood plasma dd-cfDNA with histopathology-derived rejection indices. The study found dd-cfDNA levels increased with graft inflammation, with the strongest associations in microvascular inflammation and antibody-mediated rejection. iMDx said its GraftAssure Combination Model score, which combines dd-cfDNA % and copies/mL, showed stronger correlations with four organ-health indices than percentage-only or absolute-only measures. The company said related data were previously presented at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLblzZcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","SG9999014013.SGD","BK4139","SG9999014021.USD","MDIT","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","SG9999014005.SGD","LU2095319765.USD","BK4082","BK4112","LU2210149790.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014039.USD"],"gpt_icon":0},{"id":"2619960194","title":"Second Study Affirms Superiority of Imdx Graftassure Assay’s Proprietary Dd-Cfdna Combination Model Score","url":"https://stock-news.laohu8.com/highlight/detail?id=2619960194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619960194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403223,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40104X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2616532830","title":"BRIEF-Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532830","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532830?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:07","pubTimestamp":1772543272,"startTime":"0","endTime":"0","summary":"BRIEF-Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA SubmissionMarch 3 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O:INSIGHT MOLECULAR DIAGNOSTICS COM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA435PV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMDX"],"gpt_icon":0},{"id":"2616353870","title":"Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616353870?lang=en_us&edition=fundamental","pubTime":"2026-03-02 22:15","pubTimestamp":1772460959,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Insight Molecular Diagnostics, with a price target of $12.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-insight-molecular-diagnostics-imdx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-insight-molecular-diagnostics-imdx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2614072468","title":"BRIEF-Insight Molecular Diagnostics Enters Agreement With Quest Diagnostics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614072468","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614072468?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:31","pubTimestamp":1772145088,"startTime":"0","endTime":"0","summary":"BRIEF-Insight Molecular Diagnostics Enters Agreement With Quest Diagnostics - SEC FilingFeb 26  - Insight Molecular Diagnostics Inc IMDX.O:INSIGHT MOLECULAR DIAGNOSTICS INC - ENTERS AGREEMENT WITH QUEST DIAGNOSTICS - SEC FILINGINSIGHT MOLECULAR DIAGNOSTICS INC - QUEST DIAGNOSTICS TO PROVIDE SPECIMEN COLLECTION SERVICES - SEC FILINGSource text: [ID:n0001493152-26-008169]Further company coverage: IMDX.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM2BV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMDX","BK4139"],"gpt_icon":0},{"id":"2614407163","title":"Insight Molecular Diagnostics Inc - Quest Diagnostics to Provide Specimen Collection Services - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2614407163","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614407163?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:40","pubTimestamp":1772142012,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM2BV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMDX","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}]}}